ICER panel says two ALS drug candidates have 'low' long-term value
ALS is well-known as one of the most difficult drug targets, and the US cost-effectiveness watchdog ICER isn’t quite inching closer to endorsing the two candidates.
ICER’s Midwest CEPAC (Comparative Effectiveness Public Advisory Council) met Friday to discuss clinical evidence on Amylyx’s AMX0035 and Mitsubishi Tanabe Pharma America’s intravenous version of an older ALS medicine, edaravone.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,800+ biopharma pros reading Endpoints daily — and it's free.